...
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Characterization of murine vasopressor and vasodepressor prostaglandin E(2) receptors.
【24h】

Characterization of murine vasopressor and vasodepressor prostaglandin E(2) receptors.

机译:小鼠血管加压素和血管加压素前列腺素E(2)受体的表征。

获取原文
获取原文并翻译 | 示例
           

摘要

Four E-prostanoid (EP) receptors, designated EP(1), EP(2), EP(3), and EP(4), mediate the cellular effects of prostaglandin E(2) (PGE(2)). The present studies pharmacologically characterize the vasopressor and vasodepressor EP receptors in wild-type mice (EP(2)(+/+) mice) and mice with targeted disruption of the EP(2) receptor (EP(2)(-/-) mice). Mean arterial pressure (MAP) was measured via a carotid artery catheter in anesthetized male mice. Intravenous infusion of PGE(2) decreased MAP in EP(2)(+/+) mice but increased MAP in EP(2)(-/-) mice. Infusion of EP(3)-selective agonists, including MB28767, SC46275, and sulprostone, increased MAP in both EP(2)(+/+) and EP(2)(-/-) mice. Pretreatment with SC46275 desensitized mice to the subsequent pressor effect of sulprostone, but the vasodepressor effect of PGE(2) in EP(2)(+/+) mice remained intact. Although PGE(2) alone increased MAP in EP(2)(-/-) mice, prior desensitization of the pressor effect with SC46275 allowed a residual vasodepressor effect of PGE(2) to be seen in the EP(2)(-/-) mice. An EP(4)-selective agonist (prostaglandin E(1)-OH) functioned also as a vasodepressor in both EP(2)(-/-) and EP(2)(+/+) mice. High levels of EP(3) receptor mRNA were detected in mouse aortas and rabbit preglomerular arterioles by nuclease protection, with lower expressions of EP(1), EP(2), and EP(4) mRNA. The findings suggest that combined vasodepressor effects of EP(2) and EP(4) receptors normally dominate, accounting for the depressor effects of PGE(2). In contrast, in EP(2)(-/-) mice, EP(4) receptor activity alone is insufficient to overcome the EP(3) vasopressor effect. These findings suggest that a balance between pressor and depressor PGE(2) receptors determines its net effect on arterial pressure and that these receptors may be important therapeutic targets.
机译:四个E-前列腺素(EP)受体,分别称为EP(1),EP(2),EP(3)和EP(4),介导前列腺素E(2)(PGE(2))的细胞作用。本研究从药理上表征野生型小鼠(EP(2)(+ / +)小鼠)和靶向破坏EP(2)受体(EP(2)(-/-)的小鼠中的升压药和降压药EP受体老鼠)。通过颈动脉导管在麻醉的雄性小鼠中测量平均动脉压(MAP)。 PGE(2)的静脉输注降低了EP(2)(+ / +)小鼠的MAP,但增加了EP(2)(-/-)小鼠的MAP。输注的EP(3)选择性激动剂,包括MB28767,SC46275和sulprostone,增加了EP(2)(+ / +)和EP(2)(-/-)小鼠中的MAP。用SC46275预处理的小鼠对随后的sulprostone升压作用不敏感,但是P(2)在EP(2)(+ / +)小鼠中的升压作用保持不变。虽然单独PGE(2)会增加EP(2)(-/-)小鼠中的MAP,但先前用SC46275对升压作用进行脱敏可以在EP(2)(-/)中看到PGE(2)的残余升压作用。 -) 老鼠。一个EP(4)选择性激动剂(前列腺素E(1)-OH)在EP(2)(-/-)和EP(2)(+ / +)小鼠中也起着血管降压药的作用。通过核酸酶保护作用,在小鼠主动脉和兔肾小球前小动脉中检测到高水平的EP(3)受体mRNA,而较低的EP(1),EP(2)和EP(4)mRNA表达。研究结果表明,EP(2)和EP(4)受体的联合血管舒缩作用通常占主导地位,这说明了PGE(2)的降压作用。相反,在EP(2)(-/-)小鼠中,单独的EP(4)受体活性不足以克服EP(3)血管升压作用。这些发现表明,升压药和降压药PGE(2)受体之间的平衡决定了其对动脉压的净作用,这些受体可能是重要的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号